Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing fibroblast-based cell therapies intended to address chronic diseases with high unmet medical need. The company operates within the biotechnology and regenerative medicine industries, with an emphasis on leveraging the biological properties of fibroblast cells for therapeutic applications. Its business model centers on research and development rather than commercial product sales, and it does not currently generate material operating revenue.
The company’s primary strategic positioning is based on the premise that fibroblasts may offer immunomodulatory and regenerative capabilities distinct from other cell types commonly used in cell therapy. FibroBiologics was founded in 2021 and later became a publicly traded company through a reverse merger transaction, after which it adopted its current name and strategic focus. Since inception, the company has concentrated on building a proprietary platform around fibroblast cell isolation, expansion, and therapeutic application.
Business Operations
FibroBiologics’ operations are primarily organized around research and development activities, encompassing preclinical research, early-stage clinical development, and intellectual property management. The company’s core assets consist of its fibroblast cell therapy platform, associated manufacturing processes, and licensed or internally developed intellectual property. All programs remain in the development stage, and the company has not yet commercialized any products.
Operationally, FibroBiologics conducts the majority of its activities in the United States, relying on a combination of internal scientific staff and third-party contract research organizations for laboratory studies, preclinical testing, and regulatory support. As of the most recent public disclosures, the company does not report material revenue-generating subsidiaries or joint ventures. Data inconclusive based on available public sources regarding the existence of long-term strategic partnerships beyond standard research and service agreements.
Strategic Position & Investments
The company’s strategic direction centers on advancing its fibroblast-based therapies toward clinical validation while expanding its intellectual property portfolio. Growth initiatives primarily involve progressing lead programs into early-stage clinical trials, strengthening regulatory engagement, and securing additional capital to fund development activities. FibroBiologics has publicly stated its intention to explore multiple disease indications where fibroblast biology may provide therapeutic benefit, though specific timelines remain subject to regulatory and scientific outcomes.
FibroBiologics has not announced any major acquisitions of operating companies. Its investment activity is focused internally on research programs and technology development rather than external equity investments. Any potential involvement in emerging sectors such as advanced cell manufacturing or next-generation regenerative medicine platforms remains developmental, and details beyond high-level strategic intent are limited in public disclosures. Data inconclusive based on available public sources regarding near-term acquisition plans.
Geographic Footprint
FibroBiologics is headquartered in the United States, and its operational footprint is primarily domestic. Research, management, and regulatory activities are centered in the U.S., aligning with its focus on U.S. clinical development pathways and capital markets access.
The company does not currently report material international operations or foreign subsidiaries. While future clinical trials or manufacturing partnerships may involve international sites, no sustained operational presence outside the United States has been disclosed in publicly available filings. International market entry is considered a longer-term objective contingent on successful clinical and regulatory progress.
Leadership & Governance
FibroBiologics is led by an executive team with experience in biotechnology, healthcare entrepreneurship, and capital markets. The leadership emphasizes disciplined capital allocation, protection of intellectual property, and methodical clinical development as core elements of its strategic vision. Governance is overseen by a board of directors responsible for regulatory compliance and long-term shareholder value.
Key executives include:
- Pete O’Heeron – Chief Executive Officer
- Christopher D. Shackelton – Chief Financial Officer
- Gregory L. Rader – Chief Scientific Officer
Public disclosures indicate that the leadership team’s philosophy prioritizes advancing scientifically differentiated therapies while maintaining flexibility in development strategy as clinical data emerges. Data inconclusive based on available public sources regarding the founders’ ongoing operational involvement beyond current executive roles.